Article Text

Download PDFPDF
Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation: is confirmation needed?
  1. Madalina Garbi1,
  2. Alfredo Mariani2
  1. 1 Cardiology, Royal Papworth Hospital, Cambridge, UK
  2. 2 National Guideline Centre, Royal College of Physicians, London, UK
  1. Correspondence to Dr Madalina Garbi, Cardiology, Royal Papworth Hospital, Cambridge, Cambridgeshire, UK; madalina.garbi{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Transcatheter edge-to-edge repair (TEER) may be considered in inoperable patients with severe mitral regurgitation secondary to left ventricular systolic dysfunction, who remain symptomatic despite optimal heart failure guideline-directed medical therapy including cardiac resynchronisation therapy when appropriate. All current guidelines agree in this regard. The European (ESC/EACTS) and American (ACC/AHA) professional societies guidelines define the recommendation for TEER as class IIa with level of evidence B. The UK National Institute for Heath and Care Excellence (NICE) guidelines recommend ‘consider TEER’, which is the NICE equivalent of a class II indication, by comparison with a class I indication that would have been worded as ‘offer TEER’. The weak recommendation in all guidelines reflects the uncertainty of the clinical evidence, with one randomised control trial (COAPT)1 finding symptomatic and prognostic benefit in heart failure patients with reduced left ventricular systolic function and severe secondary mitral regurgitation and one randomised control trial (MITRA-FR)2 finding no benefit. Several attempts of explaining this discrepancy were made. The generally accepted explanation is that TEER can be of benefit if the mitral regurgitation rather than the left ventricular systolic dysfunction drives the heart failure symptoms and the guidelines recommendation refers strictly to this clinical scenario.

In the UK, the introduction and use in clinical practice of novel technologies or new indications for existent technologies are regulated by NICE Technology Appraisals, NHS England Commissioning through Evaluation (CtE) supported by NICE, NHS England Clinical Commissioning Policy and Clinical Guidelines developed by NICE. Currently, TEER is commissioned by NHS England only for primary mitral regurgitation, based on the CtE study performed3 before the development of the first NICE clinical guidelines on heart valve disease.4 However, the recently published NICE clinical guidelines recommend TEER for secondary mitral regurgitation as well. Furthermore, as part of the development process of …

View Full Text


  • Twitter @MadalinaGarbi

  • Contributors Both authors have made substantive intellectual contributions to this editorial. MG wrote the first draft and ensured validity of the document from a medical perspective. AM provided the health economic analysis of the paper the editorial was written for and all information regarding health economics.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles